Functional Role of the L396R Mutation of Tks5 Identified by an Exome-Wide Association Study in Atrial Fibrillation.


Journal

Circulation journal : official journal of the Japanese Circulation Society
ISSN: 1347-4820
Titre abrégé: Circ J
Pays: Japan
ID NLM: 101137683

Informations de publication

Date de publication:
25 11 2020
Historique:
pubmed: 23 10 2020
medline: 15 12 2021
entrez: 22 10 2020
Statut: ppublish

Résumé

Atrial fibrillation (AF) is the most common cardiac arrhythmia; however, the current treatment strategies for AF have limited efficacy. Thus, a better understanding of the mechanisms underlying AF is important for future therapeutic strategy. A previous study (Exome-Wide Association Study (ExWAS)) identified a rare variant, rs202011870 (MAF=0.00036, GenomAD), which is highly associated with AF (OR=3.617, P<0.0001). rs202011870 results in the replacement of Leu at 396 with Arg (L396R) in a molecule, Tks5; however, the mechanism of how rs202011870 links to AF is completely unknown.Methods and Results:The association of rs202011870 with AF was examined in 3,378 participants (641 control and 2,737 AF cases) from 4 independent cohorts by using an Invader assay. Consequences of rs202011870 in migration ability, podosome formation, and expression of inflammation-related molecules in macrophages were examined using RAW264.7 cells with a trans-well assay, immunocytochemistry, and qPCR assay. Validation of the association of rs202011870 with AF was successful. In vitro studies showed that RAW264.7 cells with L396R-Tks5 increased trans-well migration ability, and enhanced podosome formation. RAW264.7 cells with L396R-Tks5 also increased the expression of several inflammatory cytokines and inflammation-related molecules. L396R mutation in Tks5 associated with AF enhances migration of macrophages and their inflammatory features, resulting in enhanced susceptibility to AF.

Sections du résumé

BACKGROUND
Atrial fibrillation (AF) is the most common cardiac arrhythmia; however, the current treatment strategies for AF have limited efficacy. Thus, a better understanding of the mechanisms underlying AF is important for future therapeutic strategy. A previous study (Exome-Wide Association Study (ExWAS)) identified a rare variant, rs202011870 (MAF=0.00036, GenomAD), which is highly associated with AF (OR=3.617, P<0.0001). rs202011870 results in the replacement of Leu at 396 with Arg (L396R) in a molecule, Tks5; however, the mechanism of how rs202011870 links to AF is completely unknown.Methods and Results:The association of rs202011870 with AF was examined in 3,378 participants (641 control and 2,737 AF cases) from 4 independent cohorts by using an Invader assay. Consequences of rs202011870 in migration ability, podosome formation, and expression of inflammation-related molecules in macrophages were examined using RAW264.7 cells with a trans-well assay, immunocytochemistry, and qPCR assay. Validation of the association of rs202011870 with AF was successful. In vitro studies showed that RAW264.7 cells with L396R-Tks5 increased trans-well migration ability, and enhanced podosome formation. RAW264.7 cells with L396R-Tks5 also increased the expression of several inflammatory cytokines and inflammation-related molecules.
CONCLUSIONS
L396R mutation in Tks5 associated with AF enhances migration of macrophages and their inflammatory features, resulting in enhanced susceptibility to AF.

Identifiants

pubmed: 33087629
doi: 10.1253/circj.CJ-20-0101
doi:

Substances chimiques

Adaptor Proteins, Vesicular Transport 0
SH3PXD2A protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2148-2157

Auteurs

Xiaoxi Yang (X)

Department of Bio-information Pharmacology, Medical Research Institute, Tokyo Medical and Dental University.
Department of Cardiovascular Medicine, The First Hospital of China Medical University.

Tetsuo Sasano (T)

Department of Biofunctional Informatics, Graduate School of Medicine, Tokyo Medical and Dental University.
Department of Cardiovascular Medicine, Graduate School of Medicine, Tokyo Medical and Dental University.

Yusuke Ebana (Y)

Department of Bio-information Pharmacology, Medical Research Institute, Tokyo Medical and Dental University.
Life Science and Bioethics Research Center, Tokyo Medical and Dental Science.

Jun K Takeuchi (JK)

Department of Bio-information Pharmacology, Medical Research Institute, Tokyo Medical and Dental University.

Kensuke Ihara (K)

Department of Bio-information Pharmacology, Medical Research Institute, Tokyo Medical and Dental University.

Masahiro Yamazoe (M)

Department of Bio-information Pharmacology, Medical Research Institute, Tokyo Medical and Dental University.
Department of Biofunctional Informatics, Graduate School of Medicine, Tokyo Medical and Dental University.

Tetsushi Furukawa (T)

Department of Bio-information Pharmacology, Medical Research Institute, Tokyo Medical and Dental University.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH